Kuo G, Choo QL, Alter HJ, Gitnick GL, Redeker AG, Purcell RH, Miyamura T, Dienstag
JL, Alter MJ, Stevens CE, Tegtmeier GE, Bonino F, Colombo M, Lee WS, Kuo C, Berger K,
Shuster JR, Overby LR, Bradley DW, Houghton M (1989) An assay for circulating antibodies
to a major etiologic virus of human non-A, non-B-hepatitis. Science 244:362–364
Strader DB, Wright T, Thomas DL, Seeff LB, American Association for the Study of Liver D
(2004) Diagnosis, management, and treatment of hepatitis C. Hepatology 39:1147–1171
de Martel C, Maucort-Boulch D, Plummer M, Franceschi S (2015) World-wide rela-
tive contribution of hepatitis B and C viruses in hepatocellular carcinoma. Hepatology
62:1190–1200
Wasley A, Alter MJ (2000) Epidemiology of hepatitis C: geographic differences and temporal
trends. Semin Liver Dis 20:1–16
Simmonds P (2013) The origin of hepatitis C virus. Curr Top Microbiol Immunol
369:1–15
McMahon BJ, Alward WL, Hall DB, Heyward WL, Bender TR, Francis DP, Maynard JE
(1985) Acute hepatitis B virus infection: relation of age to the clinical expression of disease
and subsequent development of the carrier state. J Infect Dis 151:599–603
Moradpour D, Penin F, Rice CM (2007) Replication of hepatitis C virus. Nat Rev Microbiol
5:453–463
Romero-Brey I, Merz A, Chiramel A, Lee JY, Chlanda P, Haselman U, Santarella-Mellwig
R, Habermann A, Hoppe S, Kallis S, Walther P, Antony C, Krijnse-Locker J, Bartenschlager
R (2012) Three-dimensional architecture and biogenesis of membrane structures associated
with hepatitis C virus replication. PLoS Pathog 8:e1003056
Gill K, Ghazinian H, Manch R, Gish R (2016) Hepatitis C virus as a systemic disease: reach-
ing beyond the liver. Hepatol Int 10:415–423
Kohli A, Shaffer A, Sherman A, Kottilil S (2014) Treatment of hepatitis C: a systematic
review. JAMA 312:631–640
Foster GR, Irving WL, Cheung MC, Walker AJ, Hudson BE, Verma S, McLauchlan J,
Mutimer DJ, Brown A, Gelson WT, MacDonald DC, Agarwal K, Hcv Research UK (2016)
Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompen-
sated cirrhosis. J Hepatol 64:1224–1231
Sulkowski MS, Vargas HE, Di Bisceglie AM, Kuo A, Reddy KR, Lim JK, Morelli G, Darling
JM, Feld JJ, Brown RS, Frazier LM, Stewart TG, Fried MW, Nelson DR, Jacobson IM,
Group H-TS (2016) Effectiveness of Simeprevir Plus Sofosbuvir, with or without ribavirin,
in real-world patients with HCV genotype 1 infection. Gastroenterology 150:419–429
Lawitz E, Makara M, Akarca US, Thuluvath PJ, Preotescu LL, Varunok P, Morillas RM,
Hall C, Mobashery N, Redman R, Pilot-Matias T, Vilchez RA, Hezode C (2015) Efficacy
and safety of ombitasvir, paritaprevir, and ritonavir in an open-label study of patients with
genotype 1b chronic hepatitis C virus infection with and without cirrhosis. Gastroenterology
149:971–980. e971
Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, Shiffman ML,
Wedemeyer H, Berg T, Yoshida EM, Forns X, Lovell SS, Da Silva-Tillmann B, Collins CA,
Campbell AL, Podsadecki T, Bernstein B (2014) ABT-450/r-ombitasvir and dasabuvir with
ribavirin for hepatitis C with cirrhosis. N Engl J Med 370:1973–1982
Reddy KR, Bourliere M, Sulkowski M, Omata M, Zeuzem S, Feld JJ, Lawitz E, Marcellin P,
Welzel TM, Hyland R, Ding X, Yang J, Knox S, Pang P, Dvory-Sobol H, Subramanian GM,
Symonds W, McHutchison JG, Mangia A, Gane E, Mizokami M, Pol S, Afdhal N (2015)
Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and com-
pensated cirrhosis: an integrated safety and efficacy analysis. Hepatology 62:79–86
Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS Jr, Fried MW, Terrault
NA, O’Leary JG, Vargas HE, Kuo A, Schiff E, Sulkowski MS, Gilroy R, Watt KD, Brown
K, Kwo P, Pungpapong S, Korenblat KM, Muir AJ, Teperman L, Fontana RJ, Denning J,
Arterburn S, Dvory-Sobol H, Brandt-Sarif T, Pang PS, McHutchison JG, Reddy KR, Afdhal
N, Investigators S (2015) Ledipasvir and Sofosbuvir plus ribavirin for treatment of HCV
infection in patients with advanced liver disease. Gastroenterology 149:649–659
